De Giorgi Ugo, Nicolas-Virelizier Emmanuelle, Badoglio Manuela, Bader Peter, Richard Sandrine, Maertens Johan, Lanza Francesco, Bregni Marco
*Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
Int J Gynecol Cancer. 2017 Feb;27(2):248-251. doi: 10.1097/IGC.0000000000000882.
A few small retrospective series reported results with salvage chemotherapy for malignant ovarian adult-type granulosa cell tumors (GCTs), whereas no data are available on high-dose chemotherapy (HDC) with hematopoietic progenitor cell support (HSCS) in these patients. The aim of this study was to analyze the available data of HDC for adult-type GCTs.
We conducted a retrospective analysis of ovarian cancer treated with salvage HDC registered with the European Society for Blood and Marrow Transplantation.
Of 203 adult female patients with a diagnosis of nonepithelial ovarian cancer treated with salvage HDC with HSCS and registered with the European Society for Blood and Marrow Transplantation, 4 (2%) patients were affected by GCTs. All 4 patients had ovarian adult-type GCTs that relapsed/progressed after first-line chemotherapy. The conditioning regimens included a platinum agent in all 4 patients. Bone marrow recovery was promptly achieved; neither treatment-related deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months, all patients reported a progressive disease. The patient who underwent multicycle HDC enjoyed a long-term remission of 84 months before progression and is the only one alive after 94+ months.
We showed for the first time a case with long-lasting response to salvage multicycle HDC and HSCS in adult-type GCTs.
少数小型回顾性系列报道了挽救性化疗用于恶性卵巢成人型颗粒细胞瘤（GCT）的结果，而关于这些患者接受造血祖细胞支持（HSCS）的大剂量化疗（HDC）尚无数据。本研究的目的是分析成人型GCT接受HDC的现有数据。
我们对欧洲血液与骨髓移植学会登记的接受挽救性HDC治疗的卵巢癌进行了回顾性分析。
在203例诊断为非上皮性卵巢癌并接受HSCS挽救性HDC治疗且在欧洲血液与骨髓移植学会登记的成年女性患者中，4例（2%）为GCT患者。所有4例患者均患有卵巢成人型GCT，在一线化疗后复发/进展。4例患者的预处理方案均包含铂类药物。骨髓迅速恢复；未发生与治疗相关的死亡或危及生命的毒性反应。中位随访8.5个月时，所有患者均出现疾病进展。接受多周期HDC的患者在疾病进展前有84个月的长期缓解期，是94多个月后唯一存活的患者。
我们首次展示了1例成人型GCT对挽救性多周期HDC和HSCS有持久反应的病例。
